Altasciences

Altasciences is a mid-size, fully integrated contract research organization (CRO) that specializes in early-phase drug development. Founded in 1992 by researchers from the University of Montreal, the company operates nine facilities across North America, with its headquarters in Laval, Quebec, and employs over 1,300 people. The company offers a wide range of services, including preclinical safety testing, clinical pharmacology and bioequivalence studies, bioanalytical services, and contract development and manufacturing organization (CDMO) services. Altasciences supports pharmaceutical and biotechnology companies in developing both generic medications and innovative therapies, conducting over 285 clinical trials annually with a focus on participant safety and comfort. The company is dedicated to creating a respectful environment for clinical trial participants and actively engages with local communities through various philanthropic initiatives. In 2021, Altasciences was acquired by Novo Holdings A/S, which supports its growth and expansion.